Valuation: Altimmune, Inc.

Market Cap 630M 549M 518M 471M 881M 60.42B 886M 6.19B 2.39B 30.73B 2.37B 2.31B 98.86B P/E 2026 *
-5.55x
P/E 2027 * -4.96x
Enterprise Value 190M 165M 156M 142M 265M 18.19B 267M 1.86B 720M 9.25B 713M 697M 29.76B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.58%
Yield 2026 *
-
Yield 2027 * -
1 day+0.31%
1 week-1.22%
Current month+4.50%
1 month+8.33%
3 months+23.11%
6 months-7.93%
Current year-9.97%
1 week 3.18
Extreme 3.18
3.36
1 month 2.92
Extreme 2.92
3.55
Current year 2.56
Extreme 2.56
6.44
1 year 2.56
Extreme 2.56
6.44
3 years 2.09
Extreme 2.09
14.84
5 years 2.09
Extreme 2.09
23.49
10 years 1.51
Extreme 1.51
237.3
Manager TitleAgeSince
Chief Executive Officer 58 2025-12-31
Director of Finance/CFO 70 2024-11-10
Chief Tech/Sci/R&D Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 58 2003-08-31
Chairman 78 2017-12-31
Director/Board Member 76 2012-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/13/26 Buy

Chief Executive Officer

15,000 0.0077%
7/31/26 Free

Chief Financial Officer

1,753 0.0009%
7/31/26 Free

Chief Technology Officer

875 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+0.31%-1.22%-8.96%+11.30% 630M
-0.31%+3.56%+46.40%+100.50% 70.89B
+0.39%+1.82%+38.93%+77.73% 62.32B
-3.21%-5.72%-17.12%+350.96% 27.07B
-2.64%-0.35%-2.13%-15.04% 24.78B
+0.71%+8.50%+27.76%-15.29% 20.59B
-1.26%-10.61%+170.72%+290.48% 15.52B
-0.22%+1.62%+44.31%+167.58% 14.49B
+0.73%+5.00%-1.33%+854.55% 14.14B
-0.54%-0.30%+27.33%+202.19% 12.35B
Average -0.49%+1.36%+32.59%+202.50% 26.28B
Weighted average by Cap. -0.53%+1.38%+35.68%+160.98%

Financials

2026 *2027 *
Net sales - -
Net income -100M -87.49M -82.58M -75.03M -141M -9.63B -141M -988M -381M -4.9B -377M -369M -15.76B -123M -107M -101M -91.95M -172M -11.81B -173M -1.21B -468M -6B -463M -452M -19.32B
Net Debt -440M -384M -362M -329M -616M -42.23B -619M -4.33B -1.67B -21.48B -1.65B -1.62B -69.09B -332M -289M -273M -248M -464M -31.8B -466M -3.26B -1.26B -16.17B -1.25B -1.22B -52.03B
Logo Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
57
Date Price Change Volume
26-09-18 US$3.250 +0.31% 12,175,391
26-09-17 US$3.240 0.00% 3,457,393
26-09-16 US$3.240 +0.31% 3,331,820
26-09-15 US$3.230 -2.12% 2,339,114
26-09-14 US$3.300 +0.92% 2,465,554
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.240USD
Average target price
17.22USD
Spread / Average Target
+431.55%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!